Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
C4x Discovery Holdings Plc LSE:C4XD London Ordinary Share GB00BQQ2RV18 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.35 -1.97% 17.40 17.30 17.50 17.50 17.30 17.50 36,754 16:35:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -5.9 -2.0 - 44

C4x Discovery Share Discussion Threads

Showing 2676 to 2699 of 2850 messages
Chat Pages: 114  113  112  111  110  109  108  107  106  105  104  103  Older
DateSubjectAuthorDiscuss
02/12/2021
09:57
Il second that
bloomberg2
02/12/2021
09:47
I'm inferring good things from the appointment of Dr Mario Polywka
t0pgrader
26/11/2021
20:04
Even after the short term profit taking today, this share has risen sharply from 29p over the last few weeks. There is so much going on behind the scenes, update on trial for first INDV deal, another molecule deal has been close for some time and new molecules will no doubt emerge very soon.

Personally, if the market continues to undervalue the potential for this one, I would not be surprised at a takeover bid from a third party or the management. The bulk of the fund raising work has been done - future milestone payments/deals and, hopefully, regular income will see this company self funding very soon.

alloa2003
26/11/2021
10:31
Starting to get very interesting here.

Will there be any more rns before?

Wednesday, December 8th 2021
Full Year 2021 C4X Discovery Holdings PLC Earnings Release

charlie9038
26/11/2021
10:26
C4X Discovery Holdings plc("C4XD", "C4X Discovery" or the "Company")C4X Discovery CEO, Clive Dix, receives OBN Special Recognition Award 202126 November 2021 - C4X Discovery Holdings plc (AIM: C4XD), is honoured to announce that CEO, Dr Clive Dix has received the Special Recognition Award at the OBN 2021 Awards for his life-long contribution to the UK life sciences industry.Eva-Lotta Allan, Chairman of C4X Discovery, commented: "The prestigious OBN Awards celebrate the very best of UK life science. We are therefore very proud of all that Clive has achieved throughout his career, and in particular, here at C4XD. Clive is a veteran of the UK biotechnology industry with more than 30 years of experience, with a strong track record as a serially successful entrepreneur and an experienced pharmaceutical R&D executive. He has the scientific expertise, industry experience and leadership qualities that are needed to grow companies in such a challenging industry. Over the past year, in addition to his corporate work, Clive has played a leading role in the UK Vaccine Taskforce which has been recognised as leading one of the most successful rollouts of the COVID-19 vaccination globally. Clive is an inspiration to us here at C4XD and it is wonderful to see the recognition across the industry for all his contributions to our thriving life sciences sector."
bloomberg2
25/11/2021
17:13
Another decent sized trade gone through - someone is picking stock up
alloa2003
21/11/2021
12:21
Thanks for your comments 1aconic
alloa2003
21/11/2021
11:49
As people have mentioned on numerous occassion - if for example the INDV molecule made it to market, that would cost INDV a potential maximum £219m ($294) in payments (plus royalties on top I believe) to C4XD, then we have the other bigger deal and an even bigger one in the pipeline.

C4XD currently has a market value of £100m so INDV taking out C4XD at double the share price would be cost neutral and give them free exposure to the other deal signed and future deals. Its is all starting to hot up, this one could go anywhere

alloa2003
19/11/2021
12:59
Thinking the same alloa
bloomberg2
19/11/2021
08:09
Interesting comment from the Chief Scientific Officer Craig Fox who is leaving the company next March:-

"I wish the team well as I move on to my next role and look forward to hearing about their next achievements"

alloa2003
19/11/2021
07:37
55p would be a nice start!
alloa2003
18/11/2021
21:31
https://youtu.be/6gPzCWFcOfY4.13second in.
bloomberg2
18/11/2021
11:56
There are significant stakes from the raise at 90p in 2018 - it needs to double from here for those to get out at break even.
toffeeman
18/11/2021
11:10
1aconic,

Thats a great summary of the situation - where we are and what might happen.

Like you I think the shares are terribly underrated and are still suffering from the disasterous first fund raising a couple of years ago. At the time they expected to raise funds at 40ish, instead institutions had them over a barrel and demanded 15p on the day the deal was going to be signed off - because of "market conditions". Credibility was shot after that although slowly it is being rebuilt.

As well as everything you mention, there is a large (friendly) shareholder mopping up stock and approaching the 29.99% limit without making an offer. I am not saying they will make a bid but if more progress is made, new molecule deals, milestone payments, new molecules in the pipeline (which is surely on the way) then why not make an opportunistic bid with management.

Due to the city's disinterest the company would end up with enough funding to take it to the next stage where new deals, milestaone payments and royalties could see this turn into a cash cow in the future. If this was to happen at a giveaway price then the city would only have itself to blame.

alloa2003
18/11/2021
10:49
The full INDV trial results are (according to INDV) expected to be published by the end of their Q4. By my reckoning that's means before the end of Jan 2022. However, they've already announced that the phase one was promising and have already moved onto phase 2. What we don't however know is what milestone payments are triggered between phase one and phase two. C4XD are in a very healthy cash position at the moment and I don't personally see a scenario where another diluting fund raise would be needed in the next couple of years just for general expenses. However, the market might be prepared to give it a chunky re-rate if there was another healthy injection of cold hard cash from the INDV project milestone or another of the pipeline molecules being licensed. To my mind, that's one option for what's moving the share price currently. Also, C4XD seems currently to be very reasonably valued for an increasingly proven Biotech... you just have to compare it to the likes of Exsciencia for proof of that. All Clive Dix would have to do in the next results is to drop "progress with AI led technologies" into the report and you'd need a re-rate of 10x here to make it comparible to peers.
1aconic
18/11/2021
09:48
Results due 5th December if my memory serves me right - or thereabouts.

Plus there may be trial news from INDV and there has been talk of another even bigger deal in the pipeline for a new molecule.

alloa2003
18/11/2021
09:25
this is breaking out

news due?

mirabeau
17/11/2021
19:27
Buyers still sniffing around
alloa2003
16/11/2021
21:36
Ticking up nicely - news soon?
alloa2003
15/11/2021
23:06
No sign of a partial retracement of recent rise yet
alloa2003
11/11/2021
16:46
They can have mine for Pound a share !! Not too greedy
bloomberg2
11/11/2021
16:21
Might we see some corporate activity in C4XD in the short to medium term? The largest shareholder is buying up any stock thats available and approaching the max 29.99% without making an offer. If the market refuses to appreciate the "value" offered by the C4XD system and the two deals so far, could you blame them for an opportunistic bid?
alloa2003
11/11/2021
15:27
Nice recovery from this morning
bloomberg2
10/11/2021
20:07
They just cant keep this one down at the minute
alloa2003
Chat Pages: 114  113  112  111  110  109  108  107  106  105  104  103  Older
Your Recent History
LSE
C4XD
C4x Discov..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230205 18:13:10